The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Designing dendrimer-based lymphatic drug vectors as improved treatments for metastatic cancer. This project builds on areas of research strength in Australia (nanotechnology and biotechnology/biomaterials) and will add considerably to the expanding Australian expertise-base in dendrimer technology (in which it is a world leader). The project will advance the fundamental science base that underpins dendrimer design and has the potential to deliver substantial benefits in improved drug delivery an ....Designing dendrimer-based lymphatic drug vectors as improved treatments for metastatic cancer. This project builds on areas of research strength in Australia (nanotechnology and biotechnology/biomaterials) and will add considerably to the expanding Australian expertise-base in dendrimer technology (in which it is a world leader). The project will advance the fundamental science base that underpins dendrimer design and has the potential to deliver substantial benefits in improved drug delivery and therefore health outcomes for Australia. The interdisciplinary nature of this project will also result in a unique training program for the researchers involved. Such experience is in great demand in Australia where the developing biotechnology and nanotechnology industry is critically short of scientists with skills in drug delivery.Read moreRead less
Targeting virulence of Pseudomonas aeruginosa by inhibiting oxidative protein folding. Our research will lead to the development of compounds with a novel anti-virulence/antibacterial mode of action for further drug development.
Translating pharmacokinetic and pharmacodynamic data to better design new drugs for the treatment of Trypanosoma cruzi infection. New drugs to treat T. cruzi infection are urgently needed, however their design has been hampered by an incomplete understanding of complex host-parasite interactions, inadequate in vitro and in vivo tools to rigorously define activity during drug discovery, and a poor appreciation of concentration/effect relationships. This project aims to develop new and much needed ....Translating pharmacokinetic and pharmacodynamic data to better design new drugs for the treatment of Trypanosoma cruzi infection. New drugs to treat T. cruzi infection are urgently needed, however their design has been hampered by an incomplete understanding of complex host-parasite interactions, inadequate in vitro and in vivo tools to rigorously define activity during drug discovery, and a poor appreciation of concentration/effect relationships. This project aims to develop new and much needed in vitro methods to better define the kinetic and dynamic activity of new drug candidates, and will provide a rational basis for translating this information into lengthy animal models of T. cruzi infection. The outcome aims to be rationally designed drug candidates that are available in a shorter period of time and are suitable for further development.Read moreRead less
Nanoparticles to combat cellular dysfunction. This project aims to design, synthesise and characterise nanoparticles that can mediate the adverse effects of reactive oxygen species. The project expects to develop nanoparticles with tailored chemical functionality to modulate the concentration of reactive oxygen species and develop a platform technology for addressing conditions where reactive species are overproduced. The project will research how nanoparticles’ physicochemical properties affect ....Nanoparticles to combat cellular dysfunction. This project aims to design, synthesise and characterise nanoparticles that can mediate the adverse effects of reactive oxygen species. The project expects to develop nanoparticles with tailored chemical functionality to modulate the concentration of reactive oxygen species and develop a platform technology for addressing conditions where reactive species are overproduced. The project will research how nanoparticles’ physicochemical properties affect their activity, and how they affect cellular function, tissue morphology and particle transport in a biological milieu. The project is expected to benefit the advanced manufacturing, veterinary and medical sectors and could lead to new chemotherapeutics.Read moreRead less
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revol ....ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revolutionizing diagnosis and therapy in many diseases. The CoE will be the focus of bio-nano research activity in Australia, uniting universities, research agencies, institutes and companies. The expected outcomes are better diagnostic and therapeutic tools designed via an enhanced understanding of the bio-nano-interface.Read moreRead less
Novel antimicrobial target discovery by an integrated approach. The project aims to uncover the molecular targets of BDM-I, a novel antimicrobial candidate discovered by the start-up Australian company BioDiem Ltd. BDM-I is active against many drug resistant bacterial and fungal microorganisms and it is currently in pre-clinical development. However, the lack of resistant phenotypes makes it difficult to identify BDM-I’s mechanism of action. The project plans to use an integrated approach that c ....Novel antimicrobial target discovery by an integrated approach. The project aims to uncover the molecular targets of BDM-I, a novel antimicrobial candidate discovered by the start-up Australian company BioDiem Ltd. BDM-I is active against many drug resistant bacterial and fungal microorganisms and it is currently in pre-clinical development. However, the lack of resistant phenotypes makes it difficult to identify BDM-I’s mechanism of action. The project plans to use an integrated approach that combines a novel technique of in silico screening with experimental validation. Project outcomes are anticipated to include the first computational method to integrate target and ligand similarity for proteome-scale target and off-target discovery, which will advance the global fight against drug-resistant microorganisms.Read moreRead less
Industrial biotechnology for improved manufacture of medicinal alkaloids. Industrial biotechnology for improved manufacture of medicinal alkaloids. This project aims to develop a new semi-synthetic route for the manufacture of Codeine from Thebaine. Codeine is manufactured by the chemical conversion of poppy-derived Morphine, which is low yielding and environmentally unfriendly. This project will investigate and optimise two key enzymes in the biosynthetic pathway to Codeine and develop an innov ....Industrial biotechnology for improved manufacture of medicinal alkaloids. Industrial biotechnology for improved manufacture of medicinal alkaloids. This project aims to develop a new semi-synthetic route for the manufacture of Codeine from Thebaine. Codeine is manufactured by the chemical conversion of poppy-derived Morphine, which is low yielding and environmentally unfriendly. This project will investigate and optimise two key enzymes in the biosynthetic pathway to Codeine and develop an innovative bioreactor to achieve high yield. It will research industrial biotransformations, providing a greener and cheaper process for increased global access to Codeine. Australian opiate manufacturing is expected to benefit from value adding and increased flexibility introduced by a biotechnology approach.Read moreRead less
Chiral Catalysts by Rational Design. This project aims to integrate theory and experiment to design new catalysts for the synthesis of multi-stereocentre-containing molecules. Such molecules offer clear advantages in the area of drug design, owing to their potent and selective binding to biological targets, but a lack of available methods for their preparation currently limits their widespread use. This project will use theory to guide the discovery of new ways to make these molecules. It is exp ....Chiral Catalysts by Rational Design. This project aims to integrate theory and experiment to design new catalysts for the synthesis of multi-stereocentre-containing molecules. Such molecules offer clear advantages in the area of drug design, owing to their potent and selective binding to biological targets, but a lack of available methods for their preparation currently limits their widespread use. This project will use theory to guide the discovery of new ways to make these molecules. It is expected that detailed understanding of the factors that control stereocentre formation will be obtained from accurate theoretical modelling and will be applied to invent new catalysts that deliver improved performance and control over product structure.Read moreRead less
A bio-enabled synthesis for the glycopeptide antibiotics. This project aims to develop an in vitro biomimetic synthesis for glycopeptide antibiotics (GPAs) by combining peptide synthesis and crosslinking catalysed by biosynthetic Cytochrome P450 enzymes. The crosslinking step in GPA biosynthesis is essential for antibiotic activity but impedes their chemical synthesis. This project will study the in vitro behaviour and characteristics of the biosynthetic P450 enzymes. This will provide direct be ....A bio-enabled synthesis for the glycopeptide antibiotics. This project aims to develop an in vitro biomimetic synthesis for glycopeptide antibiotics (GPAs) by combining peptide synthesis and crosslinking catalysed by biosynthetic Cytochrome P450 enzymes. The crosslinking step in GPA biosynthesis is essential for antibiotic activity but impedes their chemical synthesis. This project will study the in vitro behaviour and characteristics of the biosynthetic P450 enzymes. This will provide direct benefits: the development of new glycopeptide antibiotic derivatives and the identification of new biocatalysts for complex chemical synthesis. Knowledge gained will also directly enable future reengineering of glycopeptide antibiotic production in vivo.Read moreRead less
Pharmacological and biochemical characterisation of Australian mygalomorph spider venoms. This project will increase our limited knowledge of Australian mygalomorph venoms by isolation, identification and characterisation of novel toxins in theraphosid and Northern mouse-spider venoms. Thereby, the scientific basis for the treatment of mygalomorph spider bites might be improved. Secondly, new insights into pharmacology and the potential development of novel therapeutics and molecular probes of t ....Pharmacological and biochemical characterisation of Australian mygalomorph spider venoms. This project will increase our limited knowledge of Australian mygalomorph venoms by isolation, identification and characterisation of novel toxins in theraphosid and Northern mouse-spider venoms. Thereby, the scientific basis for the treatment of mygalomorph spider bites might be improved. Secondly, new insights into pharmacology and the potential development of novel therapeutics and molecular probes of target molecules might be expected.Read moreRead less